Multimodality approach towards individualized non-small cell lung cancer treatment
Schaake, Eva

Citation for published version (APA):
PhD Portfolio
Graduate school Oncology Amsterdam (OOA)
PhD student          Eva E Schaake
PhD period          February 2009 - February 2014
PhD supervisors      Prof. dr. P. Baas
                    Prof. dr. M Verheij
                    Dr. J.A. Burgers
                    Dr. H.M. Klomp

Supervising committee of the Oncology graduate school Amsterdam
Dr. J.S.A. Belderbos
Prof. dr. S.C. Linn
Prof. dr. J.J.C. Neefjes

Courses
- Tumor micro environment
- Biomedical statistics
- English writing and presenting
- Radiation oncology
- EORTG good clinical practice
- Basis cursus oncologie NVvO

International conferences attended
- ESTRO 2011, London
- ASCO 2011, Chicago
- World Lung Cancer Conference 2011, Amsterdam
- ESTRO 2012, Barcelona
- European Conference Perspectives in lung cancer 2014, Amsterdam
- ESTRO 2014, Vienna
Publications

18F-Fluorodeoxyglucose Positron Emission Tomography versus Computed Tomography in predicting histopathological response to epidermal growth factor receptor - tyrosine Kinase inhibitor treatment in resectable non-small cell lung cancer.
Journal of Nuclear Medicine accepted March 2014

Quantitative determination of erlotinib and O-desmethyl erlotinib in human EDTA plasma and lung tumor tissue.
Bioanalysis. 2012 Nov;4(21):2563-77

Mediastinal lymph node position variability in non-small cell lung cancer patients treated with radical irradiation.
Radiotherapy & Oncology 2012 Nov;105(2):150-4

Tumor response and toxicity of neoadjuvant erlotinib in early stage NSCLC patients.
Journal of Clinical Oncology 2012 Aug 1;30(22):2731-8

Markers for diagnosis of mesothelioma: a systematic review and meta analysis.
British Journal of Cancer 2011 Apr 12;104(8):1325-33

Phase II trial of Uracil/Tegafur plus leucovorin and celecoxib combined with radiotherapy in locally advanced pancreatic cancer.
Radiotherapy & Oncology 2011 Feb;98(2):261-4

Cetuximab in combination with single agent daily cisplatin chemotherapy concurrent with radiotherapy in locally advanced non-small cell lung carcinoma: A feasibility study.
European Journal of Clinical & Medical Oncology 2010; 2(3):1-7
Presentations

Mediastinal lymph node position variability in lung cancer patients treated with radiotherapy
European Society of Treatment in Radiation Oncology, May 2011, London- UK.
Oral presentation

Blind prediction of response to erlotinib in early-stage non-small cell lung cancer (NSCLC) in a neoadjuvant setting based on kinase activity profiles.
American Society for Clinical Oncology, June 2011, Chicago-USA. Poster discussion

Detailed analysis of tumor regression during radical radiotherapy in lung cancer patients
World Lung Cancer Conference, July 2011, Amsterdam- the Netherlands.
Oral presentation

Tumor response and toxicity in neoadjuvant erlotinib in early stage NSCLC patients
_E.E. Schaake, H.M. Klomp and J.A. Burgers on behalf of the NEL study group._
World Lung Cancer Conference, July 2011, Amsterdam- the Netherlands.
Oral presentation

Blind prediction of response to neoadjuvant treatment with erlotinib in early stage non-small cell lung cancer (NSCLC) using kinase activity profiles.
World Lung Cancer Conference, July 2011, Amsterdam- the Netherlands.
Poster Discussion

Adaptive radiotherapy for primary lung tumours and mediastinal lymph nodes
_E.E. Schaake, J.S. Belderbos, W.A. Buikhuisen, J.-J. Sonke_
European Society of Treatment in Radiation Oncology, May 2012, Barcelona- Spain.
Oral presentation

Differential motion between mediastinal lymph nodes and primary tumor in lung cancer patients
_E.E. Schaake, M.M.G. Rossi, J.S.A. Belderbos, W.A. Buikhuisen, J.A. Burgers, J.-J. Sonke_
European Society of Treatment in Radiation Oncology, April 2014, Vienna- Austria.
Oral presentation